Mark L. Thompson

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Tribute Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, licensing and management of pharmaceuticals products in Canada. Tribute is committed to providing patients and physicians with clinically proven pharmaceuticals products that treat recognized medical conditions and diseases. Their goal is to provide quality products that improve patient outcomes. Tribute is seeking to expand its product portfolio in Canada through strategic partnerships with other pharmaceutical, biotechnology and specialty pharmaceutical companies interested in gaining market experience in Canada.

ADVANZ PHARMA Corp. Ltd. is a pharmaceutical company engages in the provision of branded and unbranded products. The firm specializes in anti-Infectives and endocrinology therapy areas. It operates through the following segments: Advanz Pharma International; Advanz Pharma North America; and Corporate. The Advanz Pharma International segment include portfolio of branded and generic products that are sold to wholesalers, hospitals, and pharmacies. The Advanz Pharma North America segment comprises branded products and authorized generic contracts that focuses primarily on the U.S. pharmaceutical market. The Corporate segment represents the centralized costs. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in St. Helier, the United Kingdom.